Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O00410

UPID:
IPO5_HUMAN

ALTERNATIVE NAMES:
Importin subunit beta-3; Karyopherin beta-3; Ran-binding protein 5

ALTERNATIVE UPACC:
O00410; B4DZA0; O15257; Q5T578; Q86XC7

BACKGROUND:
Importin-5, identified by its aliases Importin subunit beta-3, Karyopherin beta-3, and Ran-binding protein 5, is integral to the nuclear import mechanism. It serves as a receptor for nuclear localization signals, facilitating the import of substrates into the nucleus by interacting with nucleoporins and utilizing a Ran-dependent mechanism. Its significance extends to the nuclear import of various ribosomal proteins and histones, and it is involved in the nuclear import of CPEB3 following neuronal stimulation. Importin-5's function is also critical in the context of HIV-1 infection, where it assists in the nuclear import of the HIV-1 Rev protein.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Importin-5 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.